A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma

BACKGROUND: Vascular endothelial growth factor A (VEGF-A) is important in the pathogenesis of Kaposi sarcoma (KS), and bevacizumab has response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with KS. METHODS: KS patients requiring systemic therapy were...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Ramaswami, Ramya, Uldrick, Thomas S., Polizzotto, Mark N., Wyvill, Kathleen M., Goncalves, Priscila, Widell, Anaida, Lurain, Kathryn, Steinberg, Seth M., Figg, William Douglas, Tosato, Giovanna, Whitby, Denise, Yarchoan, Robert
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635024/
https://ncbi.nlm.nih.gov/pubmed/30979736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3528
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge